In the Phase III trial (ABILITY-1), patients with active non-radiographic axial spondyloarthritis were randomised to receive either adalimumab (n=91) 40mg by subcutaneous injection or placebo (n=94) every other week for 12 weeks.
Significant improvement in disease signs and symptoms, defined as a minimum 40% improvement from baseline in the Assessment of SpondyloArthritis International Society (ASAS) response criteria, was seen at week 12 in a greater proportion of the adalimumab group than the placebo group (36% vs 15%, p<0.001).
View Humira drug record
Further information: AbbVie Ltd
Follow MIMS on Twitter